Abstract
Purpose
Albendazole is a potential anticancer agent that is currently under development for the treatment of cancer. We carried out a dose-finding phase I study of oral albendazole in patients with advanced malignancies.
Patients and methods
Thirty-six patients with refractory solid tumors were enrolled. Albendazole was given orally on a day 1–14 of a 3 weekly cycle, starting at 400 mg BD with dose escalation until 1,200 mg BD. Serial blood samples were collected up to 96 h and also on day 8 of cycles 1 and 4.
Results
The maximum tolerated dose was 2,400 mg per day (1,200 BD). Myelosuppression was the main dose limiting toxicity. Fatigue and mild gastrointestinal upset were the other major adverse effects. 4 out of 24 assessable patients (16%) had a tumor marker response with a fall of at least 50% from baseline values and another patient had a prolonged period of stable marker response. A decline in plasma vascular endothelial growth factor levels was observed.
Conclusions
Albendazole was well tolerated on the schedule tested in this trial. The results of this study suggest that the recommended dose for further study is 1,200 mg twice daily for 14 days in a 21-day cycle.
This is a preview of subscription content, log in via an institution to check access.
References
Dayan AD (2003) Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics. Acta Trop 86:141–159
Marriner SE, Morris DL, Dickson B et al (1986) Pharmacokinetics of albendazole in man. Eur J Clin Pharmacol 30:705–708
Sotelo J, Jung H (1998) Pharmacokinetic optimisation of the treatment of neurocysticercosis. Clin Pharmacokinet 34:503–515
Horton J (2002) Albendazole: a broad spectrum anthelminthic for treatment of individuals and populations. Curr Opin Infect Dis 15:599–608
Lacey E, Brady RL, Prichard RK et al (1987) Comparison of inhibition of polymerisation of mammalian tubulin and helminth ovicidal activity by benzimidazole carbamates. Vet Parasitol 23:105–119
Pourgholami MH, Woon L, Almajd R et al (2001) In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole. Cancer Lett 165:43–49
Sasaki J, Ramesh R, Chada S et al (2002) The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells. Mol Cancer Ther 1:1201–1209
Khalilzadeh A, Wangoo KT, Morris DL et al (2007) Epothilone-paclitaxel resistant leukemic cells CEM/dEpoB300 are sensitive to albendazole: involvement of apoptotic pathways. Biochem Pharmacol 74:407–414
Doudican N, Rodriguez A, Osman I et al (2008) Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells. Mol Cancer Res 6:1308–1315
Yenjerla M, Cox C, Wilson L et al (2009) Carbendazim inhibits cancer cell proliferation by suppressing microtubule dynamics. J Pharmacol Exp Ther 328:390–398
Mukhopadhyay T, Sasaki J, Ramesh R et al (2002) Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo. Clin Cancer Res 8:2963–2969
Pourgholami MH, Akhter J, Wang L et al (2005) Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: in vitro and in a xenograft model of peritoneal carcinomatosis. Cancer Chemother Pharmacol 55:425–432
Martarelli D, Pompei P, Baldi C et al (2008) Mebendazole inhibits growth of human adrenocortical carcinoma cell lines implanted in nude mice. Cancer Chemother Pharmacol 61:809–817
Pourgholami MH, Yan Cai Z, Lu Y et al (2006) Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice. Clin Cancer Res 12:1928–1935
Pourgholami MH, Cai ZY, Wang L et al (2009) Inhibition of cell proliferation, vascular endothelial growth factor and tumor growth by albendazole. Cancer Invest 27:171–177
Morris DL, Jourdan JL, Pourgholami MH (2001) Pilot study of albendazole in patients with advanced malignancy. Effect on serum tumor markers/high incidence of neutropenia. Oncology 61:42–46
Cai ZY, Galettis P, Lu Y et al (2007) Pharmacokinetics of albendazole in New Zealand white rabbits: oral versus intraperitoneal administration. Anticancer Res 27:417–422
Alvarez LI, Sanchez SF, Lanusse CE (1999) In vivo and ex vivo uptake of albendazole and its sulphoxide metabolite by cestode parasites: relationship with their kinetic behaviour in sheep. J Vet Pharmacol Ther 22:77–86
Edwards G, Breckenridge AM (1988) Clinical pharmacokinetics of anthelmintic drugs. Clin Pharmacokinet 15:67–93
Lacey E, Watson TR (1985) Structure—activity relationships of benzimidazole carbamates as inhibitors of mammalian tubulin, in vitro. Biochem Pharmacol 34:1073–1077
Lacey E, Watson TR (1985) Activity of benzimidazole carbamates against L1210 mouse leukaemia cells: correlation with in vitro tubulin polymerization assay. Biochem Pharmacol 34:3603–3605
Lubega GW, Prichard RK (1991) Interaction of benzimidazole anthelmintics with Haemonchus contortus tubulin: binding affinity and anthelmintic efficacy. Exp Parasitol 73:203–213
Jordan MA, Kamath K (2007) How do microtubule-targeted drugs work? An overview. Curr Cancer Drug Targets 7:730–742
Rawden HC, Kokwaro GO, Ward SA et al (2000) Relative contribution of cytochromes P-450 and flavin-containing monoxygenases to the metabolism of albendazole by human liver microsomes. Br J Clin Pharmacol 49:313–322
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pourgholami, M.H., Szwajcer, M., Chin, M. et al. Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer. Cancer Chemother Pharmacol 65, 597–605 (2010). https://doi.org/10.1007/s00280-009-1157-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-009-1157-8